Mitazalimab (ADC-1013; JNJ-64457107) functions as an Fc??R-dependent CD40 agonist, specifically designed to exhibit tumor-directed activity. This therapeutic agent effectively activates antigen-presenting cells, such as dendritic cells (DCs), thereby initiating the activation of tumor-reactive T cells. Consequently, Mitazalimab promotes the infiltration and activation of tumor-specific T cells, which are instrumental in targeting and destroying tumor cells. Additionally, this compound plays a crucial role in remodeling the tumor-infiltrating myeloid microenvironment, enhancing its therapeutic efficacy against cancerous tissues.
Mitazalimab (ADC-1013; JNJ-64457107) functions as an Fc??R-dependent CD40 agonist, specifically designed to exhibit tumor-directed activity. This therapeutic agent effectively activates antigen-presenting cells, such as dendritic cells (DCs), thereby initiating the activation of tumor-reactive T cells. Consequently, Mitazalimab promotes the infiltration and activation of tumor-specific T cells, which are instrumental in targeting and destroying tumor cells. Additionally, this compound plays a crucial role in remodeling the tumor-infiltrating myeloid microenvironment, enhancing its therapeutic efficacy against cancerous tissues.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
